/ EN
公司动态
Company News
历年学术成果一览
时间:2023-11-27 浏览量:0


题目发表杂志发表年份IFDOI
PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via  increasing CD127+ and KLRG1+ CD8 T cellsNpj Precision  Oncology2023.0510.110.1038/s41698-023-00384-x
Implantation underneath the abdominal anterior rectus sheath enables effective and functional engraftment of stem-cell-derived isletsNature  Metabolism2023.0119.9
 
10.1038/s42255-022-00713-7
Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical TrialJAMA Oncology2022.0733.010.1001/jamaoncol.2022.2719.
Single-cell profiling of immune cells after neoadjuvant  pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC)Cell Death and Disease2022.079.710.1038/s41419-022-05057-4
PEAC: An Ultrasensitive and Cost-Effective MRD Detection System  in Non-small Cell Lung Cancer Using Plasma SpecimenFrontiers in Medicine2022.055.110.3389/fmed.2022.822200
Chemical reprogramming of human somatic cells to pluripotent  stem cellsNature2022.0469.5
 
10.1038/s41586-022-04593-5
Human Pluripotent Stem Cell-derived Islets Ameliorate Diabetes  in Nonhuman PrimatesNature Medicine2022.0287.210.1038/s41591-021-01645-7
Neoadjuvant PD-1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lungThoracic Cancer2022.023.210.1111/1759-7714.14280
Time-spatial analysis of T cell receptor repertoire in  esophageal squamous cell carcinoma patients treated with combined  radiotherapy and PD-1 blockadeOncoimmunology2022.017.710.1080/2162402X.2022.2025668
Transcriptomic and mutational analysis discovering distinct molecular characteristics among Chinese thymic epithelial tumor patientsFrontiers in Oncology2021.095.710.3389/fonc.2021.647512
Safety but limited efficacy of ensartinib in ros1-positive  non-small cell lung cancer: A single-arm, multicenter phase II studyJournal of Thoracic  Oncology2021.0720.110.1016/j.jtho.2021.06.023
Decoding the Evolutionary Response to Ensartinib in ALK-Positive  Non-Small-Cell Lung Cancer Patients by Dynamic Circulating Tumor DNA SequencingJournal of Thoracic Oncology2021.0120.110.1016/j.jtho.2021.01.1615
Integrated Multiomics Analyses Revealing Different Molecular  Profiles Between Early- and Late-Stage Lung AdenocarcinomaFrontiers in Oncology2021.015.710.3389/fonc.2021.746943
Potential predictive value of serum targeted metabolites and concurrently mutated genes for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients with EGFR sensitizing mutationsAmerican Journal of Cancer Research2020.125.9PMID: 33414999
Construction of a Human Cell Landscape at Single-cell LevelNature2020.0369.510.1038/s41586-020-2157-4
Generation of human hepatocytes from extended pluripotent stem cellsCell Research2020.0346.310.1038/s41422-020-0293-x
A two-step lineage reprogramming strategy to generate  functionally competent human hepatocytes from fibroblastsCell Research2019.0746.310.1038/s41422-019-0196-x
Long-term functional maintenance of primary human hepatocytes in vitroScience2019.0463.710.1126/science.aau7307
Identification of a novel WNK1–ROS1 fusion in a lung adenocarcinoma sensitive to crizotinibLung Cancer2019.036.110.1016/j.lungcan.2018.12.011
Efficacy, safety, and biomarker analysis of ensartinib (X-396)  in crizotinib-resistant ALK-positive non-small-cell lung cancer (NSCLC): results from a multicenter, phase II trialLancet Respiratory Medicine2019.01102.610.1016/S2213-2600(19)30252-8
Nonsmall cell lung cancer with rare exon 7 p.A289V mutation in the EGFR gene responds to Icotinib treatmentMedicine2018.121.910.1097/MD.0000000000013809


TOP